Drug Details

Information about Larotrectinib

Generic Name	Larotrectinib
IND	LOXO-101
Brand Name (US)
Manufacturer	Loxo Oncology
Drug Type
Delivery	Oral
Approval Status	Phase 2
Indications	ETV6/NTRKA fusion gene
Overall Strategy	Oncogenic Signal Path Based
Strategy	Block related tumor signal paths
Drug Category	TRK Inhibitor

Generic Name

Larotrectinib

IND

LOXO-101

Brand Name (US)

Manufacturer

Loxo Oncology

Drug Type

Delivery

Oral

Approval Status

Phase 2

Indications

ETV6/NTRKA fusion gene

Overall Strategy

Oncogenic Signal Path Based

Strategy

Block related tumor signal paths

Drug Category

TRK Inhibitor

Links
	LOXO NTRK

	LOXO-101

	Loxo Oncology TRK Inhibitor LOXO-101 Shows Durable Anti-Tumor Activity

	Transcriptome sequencing identifies ETV6–NTRK3 as a gene fusion involved in GIST

	SLITRK3 expression correlation to gastrointestinal stromal tumor risk rating and prognosis

	ARRY-470

Trials of this drug
	Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors

Trial results
	Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.

	FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.

	Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

	LOXO Corporate Update 12/19/2016

	LOXO-101 Phase 1 ESMO Asia Press Release 12/18/2016

Drug Detail